Clinical trial underway at five US hospital sites to evaluate Sense’s novel, non-invasive brain scanner to monitor intracranial hemorrhage in acute hospital setting.

LOK Corporation, and Sense Neuro Diagnostics, today announced a commercial partnership to bring innovative brain scanners being developed by Sense to the international market pending regulatory approval.

There are three devices: one for hospitals, another for ambulance use and a third for the military.
“Traumatic brain injury is the signature wound in the military today,” said Sense Neuro Diagnostics CEO Geoff Klass.

Sense Neuro Diagnostics has big plans for advancing the detection and continuous monitoring of traumatic brain injury (TBI), thanks to a $2.43 million contract from the U.S. Department of Defense. Sense was selected for the contract by the U.S. Army Medical Research and Development Command (USAMRDC) Combat Casualty Care Research Program.

More than 400,000 military personnel have suffered at least one traumatic brain injury in the last two decades. Long-term consequences for patients may have been better if doctors could more quickly have diagnosed the situation and treated it.

Sense Neuro Diagnostics, founded in 2014 by four University of Cincinnati physicians, said the $2.43 million, 18-month award from the U.S. Department of Defense will accelerate development of a new rapid, noninvasive brain scanner that can detect and continuously monitor traumatic brain injury in a battlefield or field environment.

Sense Neuro Diagnostics CTO and medical co-founder George Shaw MD, PhD presented promising new data about Sense's non-invasive triage technology at the Society of Academic Emergency Medicine's 2021 Virtual Annual Meeting.

One of Greater Cincinnati’s most promising startups has announced a new strategic collaboration with a relatively new San Francisco Bay organization that bills itself as an innovation and investment hub.

Sense Neuro Diagnostics, a medical technology company focused on improving outcomes for stroke and brain injury patients, today announced a strategic collaboration with Inflect Health, the new nationwide, multispecialty investment and innovation hub formed by Vituity.

"The fact that we can differentiate between all three stroke subtypes makes us stronger than our competition," Sense Neuro Diagnostics CEO Geoff Klass recently told reporter Liz Engel of CincyInno. "We feel very comfortable with our position. When it comes to in-hospital monitoring, we’re the only company developing a product to handle that."

When someone suffers a stroke, time to proper care is critical. As Sense Neuro CTO and medical co-founder George Shaw, MD tells TechOhio, "...Time equals brain cells, and you don’t want any detours on the way."

An underdog from the start of CincyInno's 2021 Tech Madness bracket challenge, Sense Neuro Diagnostics was the last startup standing after five head-to-head matchups and more than 3000 votes.

Sense Diagnostics, a medical technology company focused on improving outcomes for stroke and brain injury patients, announced the initiation of a multicenter pivotal trial to evaluate the safety and efficacy of a non-invasive brain scanner to monitor intracranial hemorrhage (ICH) in an acute hospital setting.

Sense Diagnostics is honored to be named Business Center Client of the Year by HCDC, Inc, an economic development organization that runs a technology business incubator, is an SBA lender, and is the Economic Development Office for Hamilton County, Ohio.

Congratulations to Geoffrey Klass, CEO of Sense Neuro Diagnostics on being selected as an Innovation Leader at the LSI 2021 Emerging Medtech Summit. For the second year in a row, Geoff Klass will be presenting to an exceptional group of investors and strategics.

Sense Neuro Diagnostics co-founder and CTO Dr. George Shaw, MD, will present clinical findings at the Society for Academic Emergency Medicine’s 2021 virtual meeting in May. The abstract accepted for presentation, “Pilot study of a non-invasive RF method to determine stroke subtype,” details Sense’s first-in human stroke differentiation study.